Single Dose vs Double dose of low molecular weight heparin in treatment of Severe Acute Pancreatitis

Phase 3

• Conditions: Health Condition 1: K859- Acute pancreatitis, unspecified

• Registration Number: CTRI/2021/01/030610
• Lead Sponsor: ILBS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

All adult cases of severe acute pancreatitis , who do not match exclusion criteria ,admitted to ILBS during study period will be included in the study .

Exclusion Criteria

Patients with:

-chronic pancreatitis.

-hypersensitivity to LMWH

-Pregnant or breast feeding ladies

- pediatric age group

- prior coagulopathy.

- CLD with acute pancreatitis.

- Stroke/ CVA(Cerebro-Vascular Accident)

- Established SP axis thrombus

- Presentation beyond 10 days from onset of pancreatitis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Objective comparison of clinical degree of severity and organ failure scores in the two arms as evaluated by SOFA, APACHE II scores at day 7 and day 14 of therapyTimepoint: Baseline, Day 7 and Day 14 of therapy.

Secondary Outcome Measures

Name	Time	Method
1.In hospital mortality. <br/ ><br>2.Duration of ICU Stay <br/ ><br>3.Duration of Hospital stay <br/ ><br> 4. Thrombotic complications- SPM-axis thrombosis <br/ ><br> 5.Haemorrhagic complications- GI haemorrhage, Intra-pancreatic haemorrhage, Post intervention haemorrhage. <br/ ><br>6.Need for IR, MIS, Surgery for local complications. <br/ ><br>7.Coagulopathy: Changes in ROTEM <br/ ><br>8.CRP level at day 3, 7, 14 <br/ ><br>Timepoint: At admission, day 3, day 7, day 14 and throughout hospital stay depending upon parameter as mentioned in secondary outcome parameteres.